Oncology Leads Personalized Medicine
Applied Clinical Trials
Study finds that almost 75% of cancer drug candidates rely on biomarker data.
The opportunity to more precisely target and to personalize medical treatments based on biomarker data has attracted growing interest from biopharmaceutical companies. A recent study by the Tufts Center for the Study of Drug
Number of compounds in R&D that rely on biomarker data.
Development (Tufts CSDD) finds that oncology dominates personalized medicine product development in part because cancer-related illnesses are extremely complex and they receive the highest level of R&D activity. Companies involved in developing personalized medicines report that across all phases, 73% of oncology drugs now rely on biomarker data. This compares with 42% of compounds in all indications.
- Tufts CSDD
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
